VirtualCareFinder may earn a commission when you visit a provider through our links.
Two Paths to GLP-1 Treatment
Patients pursuing GLP-1 medications for weight management face a fundamental choice: FDA-approved brand-name medications like Wegovy and Zepbound, or compounded versions of semaglutide and tirzepatide prepared by compounding pharmacies. The two options differ meaningfully in safety profile, cost, regulatory status, and availability.
What Are FDA-Approved GLP-1 Medications?
FDA-approved GLP-1 receptor agonists for weight management include Wegovy (semaglutide) by Novo Nordisk (approved 2021) and Zepbound (tirzepatide) by Eli Lilly (approved 2023). These went through extensive clinical trials involving thousands of patients. Other GLP-1 medications like Ozempic and Mounjaro are FDA-approved for type 2 diabetes and used off-label for weight loss.
What you get with FDA-approved medications: clinical trial data from thousands of patients, consistent cGMP manufacturing, FDA post-market surveillance, established dosing protocols, insurance coverage potential, and known drug interaction profiles.
What Are Compounded GLP-1 Medications?
Compounded semaglutide and tirzepatide are versions of the same active ingredients prepared by compounding pharmacies. Under federal law, compounding pharmacies can produce copies of FDA-approved drugs when the FDA designates the drug as being in shortage. Both semaglutide and tirzepatide have been subject to shortage designations due to massive demand.
What you get: lower cost ($79 to $299/month vs. $800 to $1,300), faster access without prior authorization, the same active pharmaceutical ingredient, and preparation by licensed pharmacies. What you do not get: clinical trial data for the specific formulation, cGMP manufacturing standards, FDA post-market surveillance, guaranteed long-term availability, or insurance coverage.
Safety Considerations
Manufacturing Quality. FDA-approved manufacturers operate under cGMP regulations with regular FDA inspections. Compounding pharmacies operate under state pharmacy board oversight and follow USP 797/800 standards. Quality varies between pharmacies — some operate near pharmaceutical-grade levels, others have less rigorous controls.
Formulation Differences. Compounded versions may use different inactive ingredients, different concentrations, and different delivery devices (standard vials with syringes rather than proprietary autoinjectors).
Side Effects. The expected side effects — nausea, vomiting, diarrhea, constipation, injection site reactions — are similar for both since the active ingredient is the same. However, formulation differences could theoretically affect the side effect profile.
Cost Comparison
| Feature | FDA-Approved (Brand-Name) | Compounded |
|---|---|---|
| Monthly cost without insurance | $800-$1,300 | $79-$299 |
| Monthly cost with insurance | $25-$150 (copay) | Not typically covered |
| Annual cost without insurance | $9,600-$15,600 | $948-$3,588 |
| Prior authorization required | Y | N |
| Savings programs available | Y | N |
Which Telehealth Providers Offer Which
Brand-name only: Calibrate prescribes Wegovy, Zepbound, Mounjaro, and Ozempic exclusively. Works with insurance and handles prior authorizations.
Compounded (and sometimes brand-name):Hims & Hers (primarily compounded, cash-pay), Ro (both options), Found (both options with insurance support), Mochi Health (both options), WW Clinic (compounded with some brand-name access), Sesame Care (compounded semaglutide, marketplace model), and Sprout Health (compounded semaglutide and tirzepatide, price-lock guarantee).
The Regulatory Landscape: What Has Changed and What Is Still Shifting
The legal basis for compounding GLP-1 medications depends on FDA shortage designations. When a drug is on the FDA's drug shortage list, Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act permit compounding pharmacies to produce copies of the drug.
Semaglutide was added to the FDA shortage list in 2022 due to unprecedented demand for Ozempic and Wegovy. Tirzepatide (Mounjaro/Zepbound) followed as it launched. This created a legal window for compounding pharmacies to produce these medications at scale.
In early 2025, the FDA began the process of removing semaglutide from the shortage list after Novo Nordisk increased supply. This triggered a legal challenge from compounding pharmacies and significant regulatory uncertainty. The FDA subsequently extended the compliance period for 503A compounders (smaller, patient-specific pharmacies) while 503B outsourcing facilities faced tighter restrictions.
As of 2026, the regulatory landscape remains unsettled. Some telehealth platforms have transitioned patients to alternative formulations (combining semaglutide with other compounds like B12 or L-carnitine) that may allow continued compounding under different legal frameworks. Others have pivoted entirely to tirzepatide, which has had its own shortage designations.
What this means for patients:If you are using or considering compounded GLP-1 medications, availability may change with limited notice. Ask your telehealth platform directly about their pharmacy's regulatory status and what options they offer if compounded versions become unavailable.
Questions to Ask Your Telehealth Provider About Compounding
Not all compounded GLP-1 programs are equivalent. These questions help you understand what you are getting:
- Which compounding pharmacy produces your medication? Ask for the specific name so you can verify accreditation independently.
- Is the pharmacy PCAB-accredited or operating under 503B status? 503B outsourcing facilities are held to higher FDA standards than 503A pharmacies.
- Does the pharmacy conduct third-party batch testing? Look for certificate of analysis (COA) availability for each batch.
- What formulation will I receive? Confirm whether it is base semaglutide/tirzepatide or a combination formulation, and what the inactive ingredients are.
- What happens if compounded versions become unavailable? Understand your options before you need them.
- What device delivers the medication? Compounded versions use standard syringes and multi-dose vials, not proprietary autoinjectors like Wegovy's pen. Ask for administration guidance if you have never self-injected before.
How to Evaluate Compounding Pharmacy Quality
- Accreditation. Look for PCAB (Pharmacy Compounding Accreditation Board) accreditation.
- State licensing. Verify the pharmacy is licensed in your state.
- Third-party testing. Ask whether the pharmacy tests every batch independently.
- FDA inspection history. Check for warning letters or enforcement actions.
- Telehealth platform vetting. Ask your provider how they selected their compounding pharmacy partner.
Making Your Decision
Consider FDA-approved brand-name medications if
Your insurance covers them, you prioritize established safety and efficacy data from clinical trials, you want cGMP-manufactured product consistency, or long-term availability certainty matters to you.
Consider compounded medications if
Insurance does not cover brand-name options and cost is a barrier, you understand and accept the different risk profile, your provider has vetted the compounding pharmacy, and you are aware availability may change with regulatory shifts.
Explore GLP-1 Providers
Browse GLP-1 telehealth providers on VirtualCareFinder to compare which platforms offer brand-name versus compounded medications, their pricing, and their insurance support.